Team uncovers novel epigenetic changes in leukemia

May 10, 2017, University of Texas Health Science Center at San Antonio
Ricardo Aguiar, M.D., Ph.D., of UT Health San Antonio, led a research team that reports in Cancer Cell on a finding in IDH-mutant cancers. Credit: UT Health San Antonio

UT Health San Antonio researchers discovered epigenetic changes that contribute to one-fifth of cases of acute myeloid leukemia (AML), an aggressive cancer that arises out of the blood-forming cells in bone marrow.

The mutations also play a role in a large majority of low-grade gliomas, which are among the most-treatable brain tumors.

The UT Health scientists describe the finding in this week's issue of Cancer Cell.

"The best way to treat a is to understand it," said Ricardo C.T. Aguiar, M.D., Ph.D., professor of medicine at The University of Texas Health Science Center, now called UT Health San Antonio. "We have added to the understanding of a broad swath of cancers that carry what is called the IDH mutation."

Cancers classified by genetic defect

Dr. Aguiar, a hematology-oncology researcher and member of the UT Health San Antonio Cancer Center, is senior author of the study. He said in the future cancers will be classified not by where they are located but by their genetic defect - such as the IDH mutation. IDH is short for isocitrate dehydrogenase.

The UT Health team found that IDH mutations alter an epigenetic process called RNA methylation, which leads to deregulation of hundreds of other genes and processes inside the tumor cell.

Changes that amplify—or silence—genes

Epigenetic modifications change gene activity but don't structurally change the body's genetic blueprints. Diet, aging, environmental exposure and other factors can prompt that amplify or silence certain genes.

A drug that inhibits the IDH mutant enzymes is in non-UT Health-related clinical trials. The UT Health discovery provides evidence for why the drug may help patients with AML and low-grade gliomas.

A difficult-to-treat form of leukemia

"Acute myeloid leukemia remains a very difficult-to-treat tumor and, unfortunately, the majority of patients still die of their disease," Dr. Aguiar said. "In this paper, in addition to sophisticated genetic models created in our lab, we also studied primary AML samples to demonstrate that, in the very IDH-mutant tumors from the patients, we detected this change in RNA methylation. By better understanding how the IDH-dependent cancers work, we may be able to fine-tune future therapies and improve survival."

Explore further: Genetic mutations help brain tumors evade targeting by immunotherapy treatments

More information: Sara M. Elkashef et al, IDH Mutation, Competitive Inhibition of FTO, and RNA Methylation, Cancer Cell (2017). DOI: 10.1016/j.ccell.2017.04.001

Related Stories

Genetic mutations help brain tumors evade targeting by immunotherapy treatments

March 20, 2017
Tumors of the brain and spinal cord, or gliomas, are among the most commonly occurring brain tumors. Although a majority of gliomas are classified as curable, these low-grade tumors have the potential to develop more aggressive ...

Two genetic mutations discovered in subset of acute myeloid leukemia

December 7, 2016
Two genetic mutations known to play a role in many solid cancers might also help explain why a subset of acute myeloid leukemia (AML) patients develop the disease, according to new research from The Ohio State University ...

Cancer cells disguise themselves by switching off genes, new research reveals

March 30, 2017
Scientists have uncovered how tumor cells in aggressive uterine cancer can switch disguises and spread so quickly to other parts of the body. In a study published in Neoplasia, researchers at the Washington University School ...

Epigenetic diversity in childhood cancer

January 30, 2017
Tumors of the elderly, such as breast cancer and colon cancer, accumulate thousands of DNA mutations. These genetic defects contribute to cancer-specific properties including uncontrolled growth, invasion in neighboring tissues, ...

Scientists identify key defect in brain tumor cells

February 1, 2017
In a new study, Yale researchers identified a novel genetic defect that prevents brain tumor cells from repairing damaged DNA. They found that the defect is highly sensitive to an existing FDA-approved drug used to treat ...

Lymphomas tied to metabolic disruption

July 17, 2015
Researchers from the School of Medicine at The University of Texas Health Science Center at San Antonio have found evidence that directly links disrupted metabolism (energy production in cells) to a common and often fatal ...

Recommended for you

Study suggests well-known growth suppressor actually fuels lethal brain cancers

June 18, 2018
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it ...

Genomics offers new treatment options for infants with range of soft tissue tumors

June 18, 2018
The genetic causes of a group of related infant cancers have been discovered by scientists at the Wellcome Sanger Institute, the University of Wuerzburg and their collaborators. Whole genome sequencing of tumours revealed ...

Standard myelofibrosis drug can awaken 'dormant' lymphoma

June 18, 2018
Most patients with myelofibrosis, a rare chronic disorder of the haematopoietic cells of the bone marrow, benefit from drugs from the JAK2 inhibitor class: symptoms are relieved, survival extended and general quality-of-life ...

Breast cancer researcher warns against online genetic tests

June 18, 2018
We have never been so fascinated by the secrets inside our cells.

Non-coding DNA reveals a route by which advanced prostate cancer resists treatment

June 15, 2018
Two research teams converge on epigenetic switches that feed treatment-resistant metastatic prostate tumors. This research highlights the value of exploring gene regulation and large-scale structural changes in the cancer ...

Researchers peer inside cells to spy on cancer's on-off switch

June 15, 2018
Forty years after researchers first discovered it in fruit flies, a once-obscure cluster of proteins called PRC2 has become a key target for new cancer-fighting drugs, due to its tendency—when mutated—to bind to and silence ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.